Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical's Q1 Sales Bounce 50 Percent

NEW YORK (GenomeWeb News) – Response Biomedical today reported that product sales for the first quarter rose 50 percent year over year on the strength of its cardiovascular tests.

The Vancouver, British Columbia-based firm recorded product sales of C$3 million (US$3 million) for the three months ended March 31, up from $2 million a year ago, as cardiovascular sales increased 80 percent year over year to $2.7 million from $1.5 million. Improved performance in China was the primary driver of growth in the cardiovascular business, Response Biomedical said.

Sales of its infectious disease, biodefense, and vector infectious disease products were down 39 percent to $C300,000 from C$490,000 a year ago. The company had no contract service fees and revenues, compared to C$448,104 a year ago.

Operating expenses increased 6 percent to C$1.8million from C$1.7 million a year ago as R&D and SG&A expenses increased, the company said.

The firm's net loss for the period rose to C$5.7 million, or C$.04 per share, compared to a net loss of C$1.5 million, or C$.04 per share, a year ago. The increase was due primarily to a C$5 million non-cash expense incurred due to a change in valuation of Response Biomedical's warrant liability for the first quarter, which did not exist in the year-ago period, the company said.

Adjusted net loss for the quarter was C$700,000, or C$.01 per share.

"The business performance of Response shows continued improvement as a result of our focus on higher margin products and active management of our distribution channels coupled with leadership changes and right-sizing our operations," Response Biomedical Executive Chairman and Interim CEO Peter Thompson said in a statement. "The organization remains committed to accelerating our path to profitable growth."

Response Biomedical announced last month the hiring of Jeff Purvin to be its CEO.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.